Abstract
Objective To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG).
Background LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related co-morbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain.
Methods Prospective data was collected from 23 enrolled human subjects from a single institution. Parameters of weight, co-morbidities, and trends in blood biomarkers and leukocyte subsets were observed from pre-operative baseline to one year in three-month follow-up intervals. RNA-sequencing was performed on pairs of whole blood samples from the first six subjects of the study (baseline and three months post-surgery) to identify genome-wide gene expression changes associated with undergoing LSG.
Results LSG led to a significant decrease in mean total body weight loss (18.1%) at three months and among diabetic subjects a reduction in HbA1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as three months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after three months, LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism.
Conclusions LSG induces significant changes in the composition and metabolism of immune cells as early as three months post-operatively. Further evaluation is required of bariatric surgery’s effects on immunometabolism and consequences for host defense and metabolic disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
D.C.C-C. was supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI) at the U.S. National Institutes of Health (NIH) (K01 HL127265). B.A.R. was supported by an NIH NHLBI grant (R01 HL086601). E.G.S. was supported by an appointed KL2 award from Harvard Catalyst (The Harvard Clinical and Translational Science Center) and the NIH National Center for Advancing Translational Sciences (NCATS) (KL2 TR002542). D.C.C.-C. and E.G.S. each received research coordinator support from the Brigham and Women's Hospital (BWH) Center for Clinical Investigation via a grant from Harvard Catalyst and the NIH NCATS (UL 1TR002541).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for the study was obtained from the Partners Human Research Committee (PHRC), the Institutional Review Board (IRB) of Partners HealthCare (IRB protocols 2015P000500 and 2015P000787).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The phenotype and gene expression data described in this study can only be shared with IRB-approved investigators within Partners HealthCare.
